Developing monoclonal antibody therapies for measles could lead to adverse pathogen evolution
Monoclonal antibody therapies are being developed to treat measles in response to its recent resurgence. These therapies risk driving measles virus evolution in ways that might undermine the protection offered by vaccination, outweighing potential benefits.
Authors
- David A. Kennedy
Institutions
- Pennsylvania State University (US)
Publication Details
- Journal
- PLoS Biology
- Published
- 2026-03-03
- DOI
- https://doi.org/10.1371/journal.pbio.3003701
- Primary Topic
- Virology and Viral Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Science Foundation
- U.S. Department of Agriculture
- National Institutes of Health